Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2015

Open Access 01-12-2015 | Poster presentation

P042. Mechanism of action and clinical evidence of botulinum toxin in chronic migraine

Authors: Giovanni Franco, Eleonora Vecchio, Marianna Delussi, Katia Ricci, Anna Montemurno, Marina de Tommaso

Published in: The Journal of Headache and Pain | Special Issue 1/2015

Login to get access

Excerpt

Considerable evidence exists supporting the notion that botulinum toxin type A (BoNT/A) can exert a direct analgesic effect in addition to its myorelaxant effect. It is likely that the benefict of using BoNT/A as prophylactic treatment for chronic migraine is due to its ability to inhibit overactivity of motor neurons and hyperexcitability of sensory neurons, by involving the suppression of peripheral and central sensitization. …
Metadata
Title
P042. Mechanism of action and clinical evidence of botulinum toxin in chronic migraine
Authors
Giovanni Franco
Eleonora Vecchio
Marianna Delussi
Katia Ricci
Anna Montemurno
Marina de Tommaso
Publication date
01-12-2015
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue Special Issue 1/2015
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/1129-2377-16-S1-A138

Other articles of this Special Issue 1/2015

The Journal of Headache and Pain 1/2015 Go to the issue

Poster presentation

P052. Patient's subjective judgement on the ease of use, speed of onset of action, efficacy and tolerability of Diclofenac sodium HPβCD (25 mg/mL) solution for subcutaneous injection vs Diclofenac potassium 50 mg for oral solution for the acute treatment of migraine

Oral presentation

O022. Migraineurs: seriously ill or basically healthy?

Poster presentation

P054. Chronic migraine and onabotulinumtoxinA: results from clinical practice

Poster presentation

P032. Coenzyme Q-10 and migraine: a lovable relationship. The experience of a tertiary headache center

Poster presentation

P024. Features of headache attributed to carotid and vertebral arteries dissection

Oral presentation

O046. Color vision and visual cortex excitability are impaired in episodic migraine. Simply coexisting or pathophysiologically related dysfunctions?